Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects
Ewing sarcoma (ES) is an aggressive malignancy driven by an oncogenic fusion protein, EWS-FLI1. Neuropeptide Y (NPY), and two of its receptors, Y1R and Y5R are up-regulated by EWS-FLI1 and abundantly expressed in ES cells. Paradoxically, NPY acting via Y1R and Y5R stimulates ES cell death. Here, we...
Main Author: | Lu, Congyi |
---|---|
Other Authors: | McGovern Institute for Brain Research at MIT |
Format: | Article |
Language: | en_US |
Published: |
Impact Journals/National Center for Biotechnology Information (U.S.)
2014
|
Online Access: | http://hdl.handle.net/1721.1/89818 |
Similar Items
-
Enhanced inhibitory control by neuropeptide Y Y5 receptor blockade in rats
by: Dec, A., et al.
Published: (2017) -
STAG2 loss reshapes oncogenic enhancer-promoter looping in Ewing sarcoma
by: Adane, Biniam, et al.
Published: (2021) -
Malignant neck mass in disguise - atypical presentation of extraskeletal Ewing's sarcoma
by: Poh, Nuan Leng, et al.
Published: (2022) -
Comprehensive evaluation of the neuropeptide-Y gene variants in the risk of obesity
by: Zain, Shamsul Mohd, et al.
Published: (2015) -
EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma
by: Iniguez, Amanda Balboni, et al.
Published: (2019)